Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of valbenazine for dyskinesia due to cerebral palsy
MOH_2023-10-18_012768Phase 3Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cerebral palsy (CP) comparing Valbenazine with Placebo (2 arms). Started Mar 2023; status: completed.
02
Drugs
valbenazine
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on MOH_2023-10-18_012768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-18_012768.